<< Вернуться к списку статей журнала

Том 26 №1 2024 год - Нефрология и диализ

Устранение пробелов в лечении почек: воплощение того, что мы знаем, в то, что мы делаем

Ликс Валери А. Таттл Кэтрин Р. Абделлатиф Дина Корреа-Роттер Рикардо Фунг Уинстан В.С. Харис Агнес Сяо Ли-Ли Халиф Макрам Кумарасвами Лата А. Лауд Фиона Рагхаван Васундхара Роумелиотис Стефанос Сьерра Марианелла Уласи Ифеома Вонг Билл Луи Сиу-Фаи Лиакопулос Вассилиос Балдуччи Алессандро

DOI: 10.28996/2618-9801-2024-1-9-22

Аннотация: Исторически сложилось так, что на процесс перехода новых методов лечения из области клинических доказательств в повседневную практику уходит в среднем 17 лет. Учитывая существование в настоящее время высокоэффективных методов лечения, позволяющих предотвратить или отсрочить развитие и прогрессирование заболеваний почек, это слишком долгий срок. Настало время сократить разрыв между тем, что мы знаем, и тем, что мы делаем. Существуют четкие рекомендации по профилактике и управлению распространенными факторами риска развития заболеваний почек, такими как гипертония и диабет, но во всем мире лишь у части людей с этими заболеваниями установлен диагноз, а еще меньше - получает целевое лечение. Аналогичным образом, подавляющее большинство людей, живущих с заболеваниями почек, не знают о своем состоянии, поскольку на ранних стадиях оно часто протекает бессимптомно. И даже среди пациентов, которым диагноз был установлен, многие не получают надлежащего лечения по поводу болезни почек. Учитывая серьезные последствия прогрессирования болезни почек - утрату функции почек или смерть - крайне важно начать лечение на ранних стадиях и должным образом. Возможности ранней диагностики и лечения заболеваний почек должны быть максимально расширены, начинаясь с уровня первичной медицинской помощи. Существует множество систематических препятствий, начиная с самих пациентов и врачей, и заканчивая уровнем системы здравоохранения и общественными факторами. Для сохранения и улучшения здоровья почек всех и каждого необходимо признать существование каждого из этих барьеров, чтобы разработать устойчивые решения и внедрять их без дальнейших задержек.

Для цитирования: Устранение пробелов в лечении почек: воплощение того, что мы знаем, в то, что мы делаем. Перевод на русский язык Е.В. Паршиной под редакцией Е.В. Захаровой. Нефрология и диализ. 2024. 26(1):9-22. doi: 10.28996/2618-9801-2024-1-9-22

Скачать Рисунок S1. Место, которое занимает нарушение функции почек как причина смерти среди факторов риска смерти 2-го уровня в зависимости от категории мирового дохода и пола
Скачать Таблица S1. Одобренные и перспективные новые лекарственные препараты для лечения различных заболеваний почек
Скачать Таблица S2. Комментарии пациентов относительно доступности, приемлемости цен, информированности, факторов, способствующих и препятствующих оптимальной нефрологической помощи

Весь текст

Ключевые слова: хроническая болезнь почек, равенство, лечение заболеваний почек, общественное здоровье, Всемирный день почки, chronic kidney disease, equity, kidney care, public health, World Kidney Day

Список литературы:

1. K.J. Jager, C. Kovesdy, R. Langham et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int 96 (2019) 1048-1050.
2. Institute for Health Metrics and Evaluation (IHME). GBD compare data visualization. Accessed November 18, 2023. http://vizhub.healthdata.org/gbd-compare.
3. V.A. Luyckx, M. Tonelli, J.W. Stanifer, The global burden of kidney disease and the sustainable development goals. Bull World Health Organ 96 (2018) 414-422D.
4. International Society of Nephrology. ISN Global Kidney Health Atlas, 3rd ed. Accessed November 18, 2023. https://www.theisn.org/initiatives/global-kidney-health-atlas/.
5. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395 (2020) 709-733.
6. R. Vanholder, L. Annemans, E. Brown et al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol 13 (2017) 393-409.
7. H.Y. Nguyen-Thi, T.N. Le-Phuoc, N. Tri Phat et al. The economic burden of chronic kidney disease in Vietnam. Health Serv Insights 14, 2021.
8. US Renal Data System. Healthcare expenditures for persons with CKD. https://usrds-adr.niddk.nih.gov/2023/chronic-kidney-disease/6-healthcare-expenditures-for-persons-with-ckd.
9. Kidney Health Australia. Transforming Australia’s kidney health: a call to action for early detection and treatment of chronic kidney disease. Accessed January 16, 2024. https://kidney.org.au/uploads/resources/Changing-the-CKD-landscape-Economic-benefits-of-early-detection-and-treatment.pdf.
10. C. Ke, J. Liang, M. Liu et al. Burden of chronic kidney disease and its risk-attributable burden in 137 low-and middle-income countries, 1990-2019: results from the global burden of disease study 2019. BMC Nephrol 23 (2022) 17.
11. E.W. Gregg, J. Buckley, M.K. Ali et al. Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact. Lancet 401 (2023) 1302-1312.
12. P. Geldsetzer, J. Manne-Goehler, M.E. Marcus et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1.1 million adults. Lancet 394 (2019) 652-662.
13. L. Chu, S.K. Bhogal, P. Lin et al. AWAREness of Diagnosis and Treatment of Chronic Kidney Disease in Adults With Type 2 Diabetes (AWARE-CKD in T2D). Can J Diabetes 46 (2022) 464-472.
14. A. Levin, M. Tonelli, J. Bonventre et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet 390 (2017) 1888-1917.
15. B. Stengel, D. Muenz, C. Tu et al. Adherence to the Kidney Disease: Improving Global Outcomes CKD guideline in nephrology practice across countries. Kidney Int Rep 6 (2021)437-448.
16. C.D. Chu, M.H. Chen, C.E. McCulloch et al. Patient awareness of CKD: a systematic review and meta-analysis of patient-oriented questions and study setting. Kidney Med 3 (2021) 576-585.e1.
17. B. Ene-Iordache, N. Perico, B. Bikbov et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Global Health 4 (2016) e307-e319.
18. B. Gummidi, O. John, A. Ghosh et al. A systematic study of the prevalence and risk factors of CKD in Uddanam, India. Kidney Int Rep 5 (2020) 2246-2255.
19. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 102 (5S) (2022) S1-S127.
20. S.B. Nicholas, K.B. Daratha, R.Z. Alicic et al. Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020. Diabetes Obes Metab 25 (2023) 2970-2979.
21. M.E. Grams, W. Yang, C.M. Rebholz et al. Risks of adverse events in advanced CKD: the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis 70 (2017) 337-346.
22. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. https://doi.org/10.1016/j.kint.2023.10.018
23. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99 (3S) (2021) S1-S87.
24. K.R. Tuttle, R.Z. Alicic, O.K. Duru et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. JAMA Netw Open 2, 2019.
25. W.W. Ismail, M.J. Witry, J.M. Urmie, The association between cost sharing, prior authorization, and specialty drug utilization: a systematic review. J Manag Care Spec Pharm 29 (2023) 449-463.
26. H.J.L. Heerspink, P. Vart, N. Jongs et al. Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials. Diabetes Obes Metab 25 (2023) 3327-3336.
27. Nuffield Department of Population Health Renal Studies Group. SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400 (2022) 1788-1801.
28. B. Fernández-Fernandez, P. Sarafidis, M.J. Soler et al. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J 16 (2023) 1187-1198.
29. P. McEwan, R. Boyce, J.J.G. Sanchez et al. Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis. Nephrol Dial Transplant 38 (2023) 1260-1270.
30. R. Vanholder, L. Annemans, M. Braks et al. Inequities in kidney health and kidney care. Nat Rev Nephrol 19 (2023) 694-708.
31. R. Agarwal, G. Filippatos, B. Pitt et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43 (2022) 474-484.
32. K.R. Tuttle, H. Bosch-Traberg, D.Z.I. Cherney et al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney Int 103 (2023) 772-781.
33. R. Rubin, It takes an average of 17 years for evidence to change practice-the burgeoning field of implementation science seeks to speed things up. JAMA 329 (2023) 1333-1336.
34. World Health Organisation. Mid-point evaluation of the implementation of the WHO global action plan for the prevention and control of noncommunicable diseases 2013-2020 (NCD-GAP). Accessed November 18, 2023. https://cdn.who.int/media/docs/default-source/documents/about-us/evaluation/ncd-gap-final-report.pdf?sfvrsn=55b22b89_5&download=true
35. M.E. Kruk, A.D. Gage, N.T. Joseph et al. Mortality due to low-quality health systems in the universal health coverage era: a systematic analysis of amenable deaths in 137 countries. Lancet 392 (2018) 2203-2212.
36. P. Kingori, K. Peeters Grietens, S. Abimbola et al. Uncertainties about the quality of medical products globally: lessons from multidisciplinary research. BMJ Glob Health 6, 2023.
37. Pan American Health Organization Quality control of medicines. Accessed November 18, 2023. https://www.paho.org/en/topics/quality-control-medicines.
38. K.R. Tuttle, L. Wong, W. St Peter et al. Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. Clin J Am Soc Nephrol 17 (2022) 1092-1103.
39. R. Kalyesubula, A.L. Conroy, V. Calice-Silva et al. Screening for kidney disease in low- and middle-income countries. Semin Nephrol 42, 2022.
40. A. Francis, M.I. Abdul Hafidz, U.E. Ekrikpo et al. Barriers to accessing essential medicines for kidney disease in low- and lower middle-income countries. Kidney Int 102 (2022) 969-973.
41. J. Rangaswami, K. Tuttle, M. Vaduganathan, Cardio-renal-metabolic care models: toward achieving effective interdisciplinary care. Circ Cardiovasc Qual Outcomes 13, 2020.
42. J.J. Neumiller, R.Z. Alicic, K.R. Tuttle, Overcoming barriers to implementing new therapies for diabetic kidney disease: lessons learned. Adv Chronic Kidney Dis 28 (2021) 318-327.
43. S.R. Mishra, D. Neupane, D. Preen et al. Mitigation of non-communicable diseases in developing countries with community health workers. Global Health 11 (2015) 43.
44. R. Joshi, O. John, V. Jha, The potential impact of public health interventions in preventing kidney disease. Semin Nephrol 37 (2017) 234-244.
45. A. Patel, D. Praveen, A. Maharani et al. Association of multifaceted mobile technology-enabled primary care intervention with cardiovascular disease risk management in rural Indonesia. JAMA Cardiol 4 (2019) 978-986.
46. A. Ardavani, F. Curtis, K. Khunti et al. The effect of pharmacist-led interventions on the management and outcomes in chronic kidney disease (CKD): a systematic review and meta-analysis protocol. Health Sci Rep 6, 2023.
47. C.F. Sherrod, S.L. Farr, A.J. Sauer, Overcoming treatment inertia for patients with heart failure: how do we build systems that move us from rest to motion?, Eur Heart J 44 (2023) 1970-1972.
48. C. Ramakrishnan, N.C. Tan, S. Yoon et al. Healthcare professionals' perspectives on facilitators of and barriers to CKD management in primary care: a qualitative study in Singapore clinics. BMC Health Services Res 22 (2022) 560.
49. J. Porter, C. Boyd, M.R. Skandari et al. Revisiting the time needed to provide adult primary care. J Gen Intern Med 38 (2023) 147-155.
50. C.A. Peralta, J. Livaudais-Toman, M. Stebbins et al. Electronic decision support for management of CKD in primary care: a pragmatic randomized trial. Am J Kidney Dis 76 (2020) 636-644.
51. P. Rios, L. Sola, A. Ferreiro et al. Adherence to multidisciplinary care in a prospective chronic kidney disease cohort is associated with better outcomes. PLoS One 17, 2022.
52. J.K. Stevenson, Z.C. Campbell, A.C. Webster et al. eHealth interventions for people with chronic kidney disease. Cochrane Database Syst Rev 8 (2019) Cd012379.
53. D.S. Tuot, S.T. Crowley, L.A. Katz et al. Usability testing of the kidney score platform to enhance communication about kidney disease in primary care settings: qualitative think-aloud study. JMIR Form Res 6, 2022.
54. W.R. Verberne, A.M. Stiggelbout, W.J.W. Bos et al. Asking the right questions: towards a person-centered conception of shared decision-making regarding treatment of advanced chronic kidney disease in older patients. BMC Med Ethics 23 (2022) 47.
55. A. Taha, Y. Iman, J. Hingwala et al. Patient navigators for CKD and kidney failure: a systematic review. Kidney Med 4, 2022.
56. B.M. Essue, M. Laba, F. Knaul et al. Economic burden of chronic ill health and injuries for households in low- and middle-income countries. in: D.T. Jamison, H. Gelband, S. Hortonet al. (Eds.), Disease Control Priorities: Improving Health and Reducing Poverty. 3rd ed. The International Bank for Reconstruction and Development/The World Bank; 2017. https://doi.org/10.1596/978-1-4648-0527-1_ch6
57. R. Khatib, M. McKee, H. Shannon et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet 387 (2016) 61-69.
58. N. Kamath, A.A. Iyengar, Chronic kidney disease (CKD): an observational study of etiology, severity and burden of comorbidities. Indian J Pediatr 84 (2017) 822-825.
59. L. Cirillo, F. Ravaglia, C. Errichiello et al. Expectations in children with glomerular diseases from SGLT2 inhibitors. Pediatr Nephrol 37 (2022) 2997-3008.
60. J.F. Donohue, J.S. Elborn, P. Lansberg et al. Bridging the "know-do" gaps in five non-communicable diseases using a common framework driven by implementation science. J Healthc Leadersh 15 (2023) 103-119.
61. Population Health Research Institute. Polypills added to WHO essential medicines list. Accessed November 18, 2023. https://www.phri.ca/eml/.
62. S.G. Sepanlou, J.F.E. Mann, P. Joseph et al. Fixed-dose combination therapy for prevention of cardiovascular diseases in CKD: an individual participant data meta-analysis. Clin J Am Soc Nephrol 18 (2023) 1408-1415.
63. V. Dev, A. Mittal, V. Joshi et al. Cost analysis of telemedicine use in paediatric nephrology-the LMIC perspective. Pediatr Nephrol 39 (2024) 193-201.
64. N. Musacchio, R. Zilich, P. Ponzani et al. Transparent machine learning suggests a key driver in the decision to start insulin therapy in individuals with type 2 diabetes. J Diabetes 15 (2023) 224-236.
65. C. Zuniga, C. Riquelme, H. Muller et al. Using telenephrology to improve access to nephrologist and global kidney management of CKD primary care patients. Kidney Int Rep 5 (2020) 920-923.
66. D.E.M. van der Horst, N. Hofstra, C.F. van Uden-Kraan et al. Shared decision making in health care visits for CKD: patients' decisional role preferences and experiences. Am J Kidney Dis 82 (2023) 677-686.
67. B. Hole, M. Scanlon, C. Tomson, Shared decision making: a personal view from two kidney doctors and a patient. Clin Kidney J 16 (2023) i12-i19.

Другие статьи по теме

• Железо (III) гидроксид олигоизомальтозат: новый препарат для коррекции дефицита железа у больных ХБП (Обзор литературы)
• Аутосомно-доминантная тубулоинтерстициальная болезнь почек вследствие мутации в гене MUC1. Обзор литературы и клиническое наблюдение
• Эффективность затрат на парикальцитол у пациентов на гемодиализе с вторичным гиперпаратиреозом
• Смешанная криоглобулинемия у пациентов с ВИЧ или ВИЧ/ВГС и признаками хронической болезни почек